Attention COVID-19 Survivors: You beat it. Now you could help fight it.
Visit TheFightIsInUs.org now to learn more about the urgent need for you to donate your strength — donate your plasma.
REIMAGINE YOUR LIFE WITH HAE
What do you want to reimagine with TAKHZYRO?
Lexi
Real TAKHZYRO patient
Reimagine your life with fewer attacks
People taking TAKHZYRO in a clinical study had attacks less often, and some people in the study had zero attacks.
In a 26-week clinical trial of 125 people with HAE 12 years of age and older, TAKHZYRO significantly reduced the number of monthly attacks, compared with placebo. People taking TAKHZYRO also had fewer moderate or severe attacks and fewer attacks requiring acute treatment, compared with placebo. And according to a supportive analysis, there were people taking TAKHZYRO who had zero attacks during the entire trial.
SELECT IMPORTANT SAFETY INFORMATION
TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:
- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives
Reimagine your dosing schedule
TAKHZYRO is a subcutaneous (under-the-skin) injection you give yourself once every 2 weeks.
The recommended dose is 300 mg every 2 weeks for people starting on TAKHZYRO.
SELECT IMPORTANT SAFETY INFORMATION
The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache.
These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1–800–FDA–1088.
Talk to your healthcare provider about TAKHZYRO
Check out the discussion guide to get started.
Personalized product support every step of the way
OnePath® helps people who have been prescribed TAKHZYRO per the approved indication get access to their medication.
SEE LEXI'S
REIMAGINE STORY
WHAT IS TAKHZYRO?
TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older.
It is not known if TAKHZYRO is safe and effective in children under 12 years of age.
IMPORTANT SAFETY INFORMATION
TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:
- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives
The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache.
These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1–800–FDA–1088.
TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.
Please see full Prescribing Information, including information for patients.